Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

April 2024

Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: Results from a randomized Phase 2 trial

Arthritis Care Res (Hoboken). 2024 Mar 26 doi: 10.1002/acr.25333 Epub ahead of print

Strand V,

Gossec L,

Coates LC,

Ogdie A,

Choi J,

Zhuo J,

Nowak M,

Deucravacitinib improved physical and social functioning, mental health, fatigue, and pain in a
Phase 2 trial in patients with active PsA. Here, investigators aimed to report the impact of deucravacitinib in a Phase 2 study in patients with active PsA from a patient perspective.

Keywords:

February 2024

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study

BMC Rheumatol. 2024 Feb 4;8(1):6 doi: 10.1186/s41927-024-00375-w

Coates L,

Rahman P,

Mease P,

Shawi M,

Xu X,

Increasing proportions of guselkumab-randomized patients met MDA domain criteria through
Week 100.

Keywords:

October 2023

Global, Regional, and National Burden of Other Musculoskeletal Disorders, 1990–2020, and Projections to 2050: A Systematic Analysis of the Global Burden of Disease Study 2021

Lancet Rheumatol 2023;5:e670–82 doi 10.1016/S2665-9913(23)00232-1

GBD 2021 Other Musculoskeletal Disorders Collaborators

As part of the GBD 2021, the authors provide updated estimates for the global burden of musculoskeletal disorders, excluding RA, osteoarthritis, low back pain, neck pain, and gout. In 2020, the total years lived with disability globally was estimated to be 42.7 million, which was a 122% increase from 1990. Over the same time period, mortality increased by 199%. The study forecasts an increase in cases by 2050 in all regions, with the exception of Central Europe.